PEPG
PepGen Inc.
$3.14
+0.10
(+3.46%)
Mkt Cap
217.19M
Volume
671,837
52W Range
1.13-7.8
Sector
Healthcare
Beta
1.89
EPS (TTM)
-1.50 USD
P/E Ratio
-3.07
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (89.66M) | (89.98M) | (78.63M) | (69.10M) | (27.28M) | (1.89M) | (1.35M) |
| EPS | -2.12 | -2.85 | -3.30 | -4.42 | -1.22 | -0.53 | -0.06 |
| Free Cash Flow | (81.90M) | (82.87M) | (71.60M) | (63.02M) | (23.10M) | (1.66M) | (914,000) |
| FCF / Share | -1.94 | -2.62 | -3.01 | -4.03 | -1.03 | -0.22 | -0.04 |
| Operating CF | (81.64M) | (82.37M) | (69.00M) | (59.27M) | (22.60M) | (1.65M) | (885,000) |
| Total Assets | 173.91M | 150.88M | 143.05M | 217.44M | 143.64M | 10.64M | 4.19M |
| Total Debt | 17.00M | 18.66M | 20.10M | 24.53M | 0 | 0 | 0 |
| Cash & Equiv | 60.51M | 49.42M | 80.77M | 181.75M | 132.90M | 9.78M | 3.49M |
| Book Value | 147.44M | 118.62M | 108.42M | 179.63M | 133.09M | 9.77M | 3.87M |
| Return on Equity | -0.61 | -0.76 | -0.73 | -0.38 | -0.20 | -0.19 | -0.35 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (17.81M) | (17.76M) | (18.34M) | (18.03M) | (23.09M) | (30.20M) | (22.24M) | (21.38M) | (28.34M) | (18.02M) | (19.50M) | (23.29M) |
| EPS | -0.26 | -0.26 | -0.43 | -0.55 | -0.70 | -0.92 | -0.68 | -0.66 | -0.87 | -0.63 | -0.82 | -0.98 |
| Free Cash Flow | (15.84M) | (18.43M) | (15.84M) | (19.36M) | (23.64M) | (23.05M) | (19.70M) | (24.20M) | (16.38M) | (22.59M) | (19.61M) | (16.91M) |
| FCF / Share | -0.23 | -0.27 | -0.38 | -0.59 | -0.72 | -0.71 | -0.60 | -0.74 | -0.50 | -0.79 | -0.82 | -0.71 |
| Operating CF | (15.81M) | (18.43M) | (15.85M) | (19.26M) | (23.60M) | (22.93M) | (19.48M) | (24.01M) | (16.35M) | (22.53M) | (19.42M) | (16.68M) |
| Total Assets | 141.40M | 156.29M | 173.91M | 190.06M | 102.24M | 127.39M | 150.88M | 170.23M | 193.51M | 207.00M | 143.05M | 164.27M |
| Total Debt | 16.09M | 16.56M | 17.00M | 17.44M | 17.86M | 18.27M | 18.66M | 19.04M | 19.41M | 19.77M | 20.10M | 20.43M |
| Cash & Equiv | 22.76M | 42.15M | 60.51M | 142.78M | 35.07M | 43.63M | 49.42M | 42.29M | 66.08M | 133.85M | 80.77M | 129.54M |
| Book Value | 119.53M | 133.98M | 147.44M | 163.14M | 71.16M | 91.81M | 118.62M | 137.46M | 155.04M | 179.00M | 108.42M | 125.86M |
| Return on Equity | -0.15 | -0.13 | -0.12 | -0.11 | -0.32 | -0.33 | -0.19 | -0.16 | -0.18 | -0.10 | -0.18 | -0.19 |
PEPG News
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG